DOK2 Has Prognostic and Immunologic Significance in Adults With Acute Myeloid Leukemia: A Novel Immune-Related Therapeutic Target.
DOK2
acute myeloid leukemia
immune microenvironment
prognostic biomarker
therapeutic target
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
12
2021
accepted:
09
02
2022
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
The role of downstream tyrosine kinase 2 (DOK2), a major member of the DOK family, remains poorly defined in acute myeloid leukemia (AML). Herein, we investigated the expression levels, clinical outcomes, and biological functions of DOK2 in patients with AML. Datasets were obtained from the Cancer Genome Atlas (TCGA) database for transcriptomic and clinical information. Nomogram construction and assessment were conducted using Cox regression analysis, receiver operating characteristic (ROC) curves, and calibration plots. Public databases, including the Gene Expression Omnibus, Cancer Cell Line Encyclopedia, LinkedOmics, GeneMANIA, TISIDB, and Gene Set Cancer Analysis, were employed for relevant bioinformatic studies. Moreover, we utilized the CIBERSORT algorithm to evaluate the level of infiltration of immune cells into the bone marrow microenvironment. We observed that DOK2 transcription levels were markedly upregulated in AML samples ( We suggest that elevated DOK2 expression could be an unfavorable prognostic indicator of survival in patients with AML. Our findings provide new insights into the role of DOK2 in AML, with promising clinical implications.
Sections du résumé
Background
UNASSIGNED
The role of downstream tyrosine kinase 2 (DOK2), a major member of the DOK family, remains poorly defined in acute myeloid leukemia (AML). Herein, we investigated the expression levels, clinical outcomes, and biological functions of DOK2 in patients with AML.
Methods
UNASSIGNED
Datasets were obtained from the Cancer Genome Atlas (TCGA) database for transcriptomic and clinical information. Nomogram construction and assessment were conducted using Cox regression analysis, receiver operating characteristic (ROC) curves, and calibration plots. Public databases, including the Gene Expression Omnibus, Cancer Cell Line Encyclopedia, LinkedOmics, GeneMANIA, TISIDB, and Gene Set Cancer Analysis, were employed for relevant bioinformatic studies. Moreover, we utilized the CIBERSORT algorithm to evaluate the level of infiltration of immune cells into the bone marrow microenvironment.
Results
UNASSIGNED
We observed that DOK2 transcription levels were markedly upregulated in AML samples (
Conclusion
UNASSIGNED
We suggest that elevated DOK2 expression could be an unfavorable prognostic indicator of survival in patients with AML. Our findings provide new insights into the role of DOK2 in AML, with promising clinical implications.
Identifiants
pubmed: 35321466
doi: 10.3389/fmed.2022.842383
pmc: PMC8935080
doi:
Types de publication
Journal Article
Langues
eng
Pagination
842383Informations de copyright
Copyright © 2022 Xu, Dong, Wang and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2014 May 1;123(18):2826-37
pubmed: 24668492
J Exp Med. 2004 Dec 20;200(12):1681-7
pubmed: 15611294
Blood. 2006 May 1;107(9):3481-5
pubmed: 16455952
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Immunol Rev. 2019 Jul;290(1):127-147
pubmed: 31355495
Oncotarget. 2015 Nov 17;6(36):39098-110
pubmed: 26517675
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Bioinformatics. 2018 Nov 1;34(21):3771-3772
pubmed: 29790900
EMBO J. 2014 Sep 1;33(17):1928-40
pubmed: 24963146
Immunol Rev. 2009 Nov;232(1):273-85
pubmed: 19909370
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963
pubmed: 29136207
J Exp Med. 2004 Dec 20;200(12):1689-95
pubmed: 15611295
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Mol Cell Neurosci. 2013 Sep;56:148-58
pubmed: 23659921
Blood Rev. 2019 Jul;36:70-87
pubmed: 31101526
J Immunol. 2016 May 15;196(10):4110-21
pubmed: 27183638
Int J Mol Sci. 2020 Apr 21;21(8):
pubmed: 32326335
Haematologica. 2010 May;95(5):819-28
pubmed: 19951971
N Engl J Med. 2010 Dec 16;363(25):2424-33
pubmed: 21067377
Int Immunol. 2007 Apr;19(4):487-95
pubmed: 17329234
J Hematol Oncol. 2020 Jun 8;13(1):72
pubmed: 32513227
Oncol Lett. 2015 Jan;9(1):241-244
pubmed: 25435967
J Immunol. 2010 Dec 15;185(12):7216-22
pubmed: 21078907
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Genes Chromosomes Cancer. 2008 Jan;47(1):8-20
pubmed: 17910043
Hematology. 2021 Dec;26(1):284-294
pubmed: 33648435
Oncol Lett. 2017 Nov;14(5):5386-5392
pubmed: 29098030
Nat Commun. 2019 Mar 25;10(1):1065
pubmed: 30911002
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Ann Surg Oncol. 2012 May;19(5):1560-7
pubmed: 22130622
Leukemia. 2011 Dec;25(12):1825-33
pubmed: 21760593
Gynecol Oncol. 2013 Aug;130(2):369-76
pubmed: 23684582
J Immunol. 2016 Nov 1;197(9):3618-3627
pubmed: 27664281
Nat Genet. 2010 Mar;42(3):216-23
pubmed: 20139980
J Cell Physiol. 2018 Sep;233(9):6604-6614
pubmed: 29150948